EAU-EANM-ESTRO-ESUR-ISUP-SIOG 前列腺癌指南 2026 年更新第二部分:复发性和转移性前列腺癌的治疗
该指南由 EAU 联合 EANM、ESTRO、ESUR、ISUP、SIOG 制定,基于 2023 至 2025 年文献更新复发、转移性激素敏感及去势抵抗性前列腺癌的治疗推荐,并为每条推荐增加证据强度评级。复发后风险分层可指导挽救治疗决策,转移性患者治疗选择已扩展至 ARPI、转移灶导向治疗、PARP 抑制剂及其联合方案和 PSMA 靶向治疗。
要点
- 复发后风险分层可指导挽救治疗决策
- 转移性前列腺癌治疗选择扩展至 ARPI、转移灶导向治疗、PARP 抑制剂及 PSMA 靶向治疗
- 指南基于临床证据,未考虑各医疗系统费用与资源差异
核心结论
- 复发、转移及去势抵抗性前列腺癌领域证据快速演进,指南体现多学科管理特征。
研究设计与样本
- 由 EAU 联合 EANM、ESTRO、ESUR、ISUP、SIOG 制定的指南,文献综述覆盖 2023 至 2025 年新数据,并对每条推荐增加基于系统评价的证据强度评级。
主要发现
- 复发后风险分层可能指导挽救治疗决策。
- 转移性前列腺癌治疗选择已拓宽,包括 ARPI、转移灶导向治疗、PARP 抑制剂及其联合方案以及 PSMA 靶向治疗。
关键数值与推荐
- 指南推荐基于临床证据,未考虑各医疗系统费用、报销结构或资源可及性差异。
临床怎么用
- 临床可依据复发后风险分层制定挽救治疗策略,并在转移性患者中综合 ARPI、转移灶导向治疗、PARP 抑制剂及 PSMA 靶向治疗等选择。
局限性
- 推荐未纳入费用、报销结构及资源可及性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: To present a summary of the 2026 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic hormone-sensitive and castration-resistant prostate cancer (PCa). METHODS: The Panel performed a literature review of new data, covering the time frame between 2023 and 2025. The Guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence. KEY FINDINGS AND LIMITATIONS: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. The range of treatment options for metastatic PCa has broadened, including androgen receptor pathway inhibitors (ARPI), metastasis-directed therapy, PARP inhibitors and their combinations, as well as PSMA-based therapy. The recommendations in the EAU Guidelines are based on clinical evidence and do not account for variations in cost, reimbursement structures, or resource availability across healthcare systems. CONCLUSIONS AND CLINICAL IMPLICATIONS: The evidence in the field of relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These PCa Guidelines reflect the multidisciplinary nature of PCa management. A full version is available from the EAU Guidelines Office or online (http://uroweb.org/guideline/ prostate-cancer/).
引用
- Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2026. PMID: 42457456. doi:10.1016/j.eururo.2026.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。